Literature DB >> 17192661

Can cholinesterase inhibitors provide additional effects to cholinergic neurotransmission enhancement?

Manuela G López1, Esperanza Arias, Mónica Sobrado, Silvia Lorrio, José M Roda, Antonio G García.   

Abstract

The most frequent of the primary degenerative dementias is Alzheimer's disease (AD). The gradual loss of memory and attention in patients suffering from this illness are accompanied by aphasia, apraxia, agnosia, and alterations in visual-spatial perception. This group of symptoms is completed by emotional alterations, psychic instability, and changes in personality that appear in advanced phases of the illness. Different histopathological alterations have been described, like marked atrophy of the cerebral cortex with loss of cortical and subcortical neurons. Other histopathological hallmarks are the formation of senile plaques composed of beta-amyloid (Abeta) and neuro fibrillary tangles composed of hyperphosphorylation of tau protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192661     DOI: 10.1385/JMN:30:1:141

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  12 in total

Review 1.  Central nicotinic receptors, neurotrophic factors and neuroprotection.

Authors:  N Belluardo; G Mudò; M Blum; K Fuxe
Journal:  Behav Brain Res       Date:  2000-08       Impact factor: 3.332

Review 2.  Cholinesterases: new roles in brain function and in Alzheimer's disease.

Authors:  Ezio Giacobini
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 3.  A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

Authors:  Paul T Francis; Agneta Nordberg; Steven E Arnold
Journal:  Trends Pharmacol Sci       Date:  2005-02       Impact factor: 14.819

4.  Synthesis and biological evaluation of tacrine-thiadiazolidinone hybrids as dual acetylcholinesterase inhibitors.

Authors:  Isabel Dorronsoro; Diana Alonso; Ana Castro; Maria del Monte; Esther García-Palomero; Ana Martínez
Journal:  Arch Pharm (Weinheim)       Date:  2005-01       Impact factor: 3.751

Review 5.  Acetylcholinesterase--new roles for an old actor.

Authors:  H Soreq; S Seidman
Journal:  Nat Rev Neurosci       Date:  2001-04       Impact factor: 34.870

6.  Abeta production as consequence of cellular death of a human neuroblastoma overexpressing APP.

Authors:  María Recuero; Elena Serrano; María J Bullido; Fernando Valdivieso
Journal:  FEBS Lett       Date:  2004-07-16       Impact factor: 4.124

7.  Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation.

Authors:  Mónica Sobrado; José M Roda; Manuela G López; Javier Egea; Antonio G García
Journal:  Neurosci Lett       Date:  2004-07-22       Impact factor: 3.046

8.  Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors.

Authors:  Esperanza Arias; Eva Alés; Nelson H Gabilan; María F Cano-Abad; Mercedes Villarroya; Antonio G García; Manuela G López
Journal:  Neuropharmacology       Date:  2004-01       Impact factor: 5.250

9.  Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.

Authors:  E K Perry; V Haroutunian; K L Davis; R Levy; P Lantos; S Eagger; M Honavar; A Dean; M Griffiths; I G McKeith
Journal:  Neuroreport       Date:  1994-03-21       Impact factor: 1.837

10.  Delayed poststroke dementia: a 4-year follow-up study.

Authors:  M Altieri; V Di Piero; M Pasquini; M Gasparini; N Vanacore; E Vicenzini; G L Lenzi
Journal:  Neurology       Date:  2004-06-22       Impact factor: 9.910

View more
  1 in total

Review 1.  Nicotinic ACh receptors as therapeutic targets in CNS disorders.

Authors:  Kelly T Dineley; Anshul A Pandya; Jerrel L Yakel
Journal:  Trends Pharmacol Sci       Date:  2015-01-29       Impact factor: 14.819

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.